Scrambler Therapy in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02111174|
Recruitment Status : Completed
First Posted : April 11, 2014
Last Update Posted : April 4, 2017
The purpose of this study is to see if Scrambler Therapy with the Calmare MC5-A machine will relieve chemotherapy induced peripheral neuropathy (CIPN).
Scrambler Therapy is a method of pain relief given with common electrocardiography (ECG) skin electrodes. The electrodes are placed on the body in pairs, and the Scrambler Therapy machine directs electrical signals across the field to simulate non-pain information.
Based on other studies, we think that we relieve pain with the Scrambler therapy device, but it has not been tested in a setting such as this one. This means that some of the pain relief could be due to placebo effect, or the CIPN pain going away on its own. In this study we want to compare the Scrambler Therapy with the sham therapy (the therapy that does not use the electrical signals). We hope that this study will help us determine if the Scrambler device really helps patients with CIPN.
Cancer patients with chronic, chemotherapy-related pain of 4 or more (on a 0-10 scale) for at least 3 months may be eligible to join this study.
|Condition or disease||Intervention/treatment|
|Neuropathy||Device: Scrambler Therapy Device: Sham Therapy|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Outcomes Assessor)|
|Primary Purpose:||Supportive Care|
|Official Title:||A Pilot Randomized Sham-Controlled Trial of MC5-A Calmare Therapy (Scrambler Therapy) in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)|
|Study Start Date :||March 2015|
|Primary Completion Date :||March 24, 2017|
|Study Completion Date :||March 24, 2017|
Experimental: Scrambler Therapy
The device is a cutaneous electrical stimulator that uses electrodes placed on the skin similar to an electrocardiogram (EKG) machine, feeling similar to a tingling or bee-sting like sensation during the therapy. The electrodes are placed in areas thought to help relieve pain associated with chemotherapy-induced peripheral neuropathy.
Device: Scrambler Therapy
Sham Comparator: Sham Therapy
The device is a cutaneous electrical stimulator that uses electrodes placed on the skin similar to an electrocardiogram (EKG) machine, feeling similar to a tingling or bee-sting like sensation during the therapy. The electrodes are placed in areas not thought to help relieve pain associated with chemotherapy-induced peripheral neuropathy.
|Device: Sham Therapy|
- Change in pain as measured by the Modified Brief Pain Index [ Time Frame: Baseline and 28 days ]To determine the change in pain from day 0 to day 28 (as measured by the Modified Brief Pain Index, question #3) with scrambler therapy in patients with chemotherapy induced peripheral neuropathy and pain (CIPN).
- Changes in the complete Brief Pain Inventory score [ Time Frame: Baseline and 28 days ]The Brief Pain Inventory (BPI) short form is a pain assessment tool used with cancer patients to measure both severity of pain and interference caused by pain on 0-10 scales.
- Changes in patient reported outcomes [ Time Frame: Baseline and 28 days ]This will be assessed using the EORTC QLQ-CIPN20, a CIPN-specific questionnaire which includes three scales assessing sensory, motor, and autonomic symptoms and functioning with each item measured on a 1-4 scale.
- Changes in pain drug use [ Time Frame: Baseline and 28 days ]This will be assessed by concomitant medication review by a study team member; all opiates will be further tabulated using a morphine oral dose equivalents table to allow better comparison between patients and arms.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02111174
|United States, Maryland|
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|
|Baltimore, Maryland, United States, 21287-0013|
|Principal Investigator:||Thomas J. Smith, MD, FACP||SKCCC at Johns Hopkins|